DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Information source: AHS Cancer Control Alberta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nausea; Neoplasms

Intervention: Olanzapine (Drug); Haldol (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Alberta Health Services

Official(s) and/or principal investigator(s):
Jose Pereira, Principal Investigator, Affiliation: Alberta Cancerboard

Summary

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Clinical Details

Official title: A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Severity of nausea on days 3 and 5

Detailed description: The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- >18 years of age

- Significant nausea/vomiting

- Failed maxeran and domperidone

- Underlying treatment of causes has failed

- Adequate cognitive function

- Communicates well

Exclusion Criteria:

- Partial/complete bowel obstruction

- Currently taking Haldol or olanzapine

- Has drug induced extrapyramidal symptoms

- Parkinson's disease

- Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus

Locations and Contacts

Tom Baker Cancer Centre, Calgary, Alberta T2N 4N2, Canada
Additional Information

Starting date: May 2005
Last updated: January 18, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017